Signature Estate & Investment Advisors LLC grew its position in shares of Pfizer Inc. (NYSE:PFE) by 15.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,131 shares of the biopharmaceutical company’s stock after acquiring an additional 1,079 shares during the quarter. Signature Estate & Investment Advisors LLC’s holdings in Pfizer were worth $298,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently made changes to their positions in PFE. Corbett Road Capital Management LLC bought a new stake in shares of Pfizer during the second quarter valued at approximately $25,000. Reitz Capital Advisors LLC bought a new position in Pfizer during the second quarter valued at approximately $29,000. Disciplined Investments LLC lifted its stake in Pfizer by 43.3% in the first quarter. Disciplined Investments LLC now owns 1,148 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 347 shares during the last quarter. Rocky Mountain Advisers LLC grew its position in Pfizer by 847.5% in the second quarter. Rocky Mountain Advisers LLC now owns 1,118 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 1,000 shares in the last quarter. Finally, JJJ Advisors Inc. bought a new stake in Pfizer in the second quarter worth approximately $44,000. 69.08% of the stock is owned by institutional investors.

Several equities research analysts recently issued reports on PFE shares. Piper Sandler lifted their price objective on shares of Pfizer from $18.50 to $24.00 in a research note on Friday, June 26th. UBS Group lifted their price objective on Pfizer from $37.00 to $39.00 and gave the company a “neutral” rating in a report on Wednesday, July 29th. Atlantic Securities lowered Pfizer from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $44.00 to $39.00 in a research note on Monday, October 12th. Morgan Stanley raised their target price on Pfizer from $36.00 to $42.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 30th. Finally, Berenberg Bank assumed coverage on Pfizer in a research report on Tuesday, September 29th. They issued a “hold” rating and a $38.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $39.64.

In other news, Director Ronald E. Blaylock acquired 13,000 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were purchased at an average cost of $38.55 per share, for a total transaction of $501,150.00. Following the transaction, the director now owns 4,000 shares of the company’s stock, valued at $154,200. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 0.08% of the stock is currently owned by corporate insiders.

Pfizer stock opened at $37.95 on Friday. The stock has a 50-day simple moving average of $36.59 and a 200 day simple moving average of $36.32. The stock has a market capitalization of $210.88 billion, a price-to-earnings ratio of 15.06, a P/E/G ratio of 2.91 and a beta of 0.67. The company has a quick ratio of 1.16, a current ratio of 1.42 and a debt-to-equity ratio of 0.78. Pfizer Inc. has a 12-month low of $27.88 and a 12-month high of $40.97.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.14. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The firm had revenue of $11.80 billion during the quarter, compared to analysts’ expectations of $11.55 billion. During the same quarter last year, the company posted $0.80 EPS. The company’s quarterly revenue was down 11.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.89 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, November 6th will be given a $0.38 dividend. This represents a $1.52 annualized dividend and a yield of 4.01%. The ex-dividend date of this dividend is Thursday, November 5th. Pfizer’s dividend payout ratio (DPR) is presently 51.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: Why are gap-down stocks important?

Want to see what other hedge funds are holding PFE? Visit to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.